Exelixis, Inc.
NASDAQ:EXELBiotechnology
+$0.34 today
- Market cap
- $17.17B
- Beta
- 0.43
- P/E (TTM)
- 16.3
- EPS (TTM)
- $3.23
Volume 1.82M
Average 2.55M
EXEL Total Liabilities
Everything the company owes to creditors and other parties.
Exelixis, Inc.NASDAQ: EXEL
Total Liabilities · Q2 FY2026 · quarter ended Jul 2026
Total liabilities broadly unchanged from a year ago
Total liabilities stood at $650.47M at the end of Q2 FY2026, up 0.9% from a year earlier and down 1.1% from the prior quarter. Over 3 fiscal years it compounded at +5.4% a year.
Context
- Total liabilities amounted to 26.1% of total assets at the end of Q2 FY2026, up 2.0 pp from a year earlier.
- Total liabilities increased in 2 of the last 3 fiscal years.
What to watch
Whether total liabilities keeps rising in the next quarterly balance sheet after a +0.9% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 683.1M USD
- Year-over-year change
- -2.9%
- 4-year CAGR
- +13.9%
| Period | Period end | Total Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2026-01-02 | 683.1M | -2.9% |
| FY2024 | 2025-01-03 | 703.49M | +3.7% |
| FY2023 | 2023-12-31 | 678.45M | +16.4% |
| FY2022 | 2022-12-31 | 583.06M | +43.7% |
| FY2021 | 2021-12-31 | 405.62M | — |
Total Liabilities vs competitors
How EXEL compares with its peers on the latest reported figures
- EXEL's Jul 2026 total liabilities of $650.47M is the 5th highest of the 8 companies compared; the peer median is $1.53B.
- Its year-over-year change of +0.9% is the 4th highest of 8, against a peer median of -0.1%.
- Total liabilities amounts to 26.1% of total assets for EXEL, versus a peer median of 39.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Sep 2026 | $67.99B | -0.7% | +3.2% | 56.8% | |
| Jun 2026 | $6.56B | +464.5% | +35.2% | 52.4% | |
| Jun 2026 | $1.72B | +204.3% | +78.7% | 39.7% | |
| Jun 2026 | $1.53B | -7.4% | +7.0% | 19.4% | |
| Jul 2026 | $650.47M | +0.9% | +5.4% | 26.1% | |
| Dec 2025 | $501.84M | -0.1% | +8.5% | 28.6% | |
| Mar 2026 | $431.05M | +1.3% | +149.9% | 91.2% | |
| Mar 2026 | $104.71M | -33.5% | -6.2% | 20.8% | |
| Peer median (excluding EXEL) | $1.53B | -0.1% | +8.5% | 39.7% | |
Competitors are the stored peer set for EXEL. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Jan 2025 | FY2025 Jan 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 647.17M | 501.2M | 262.99M | 217.37M | 482.49M |
| Short-term Investments | 819.91M | 807.27M | 732.31M | 893.9M | 576.6M |
| Net Receivables | 285.55M | 214.78M | 237.41M | 265.44M | 286.92M |
| Inventory | 27.49M | 33.3M | 17.32M | 22.39M | 21.69M |
| Other Current Assets | 54.63M | 62.21M | 67.93M | 68.48M | 75.6M |
| Total Current Assets | 1.83B | 1.62B | 1.32B | 1.47B | 1.44B |
| Property, Plant & Equipment (Net) | 104.03M | 345.44M | 470.85M | 359.11M | 441.27M |
| Goodwill | 63.68M | 63.68M | 63.68M | 63.68M | 63.68M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 |
| Long-term Investments | 371.11M | 756.73M | 728.72M | 637.29M | 603.6M |
| Tax Assets | 111.66M | 231.11M | 361.15M | 420.03M | 292.58M |
| Other Non-current Assets | 131M | 55.77M | 0 | 0 | 0 |
| Total Non-current Assets | 781.49M | 1.45B | 1.62B | 1.48B | 1.4B |
| Total Assets | 2.62B | 3.07B | 2.94B | 2.95B | 2.84B |
| Account Payables | 24.26M | 32.67M | 33.77M | 38.19M | 29.62M |
| Short-term Debt | 0 | 0 | 0 | 0 | 0 |
| Tax Payables | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue | 7.81M | 7.49M | 0 | 0 | 0 |
| Other Current Liabilities | 45.55M | 71.44M | 82.12M | 267.22M | 287.5M |
| Total Current Liabilities | 337.59M | 324.36M | 394.28M | 403.77M | 405.64M |
| Long-term Debt | 0 | 0 | 0 | 0 | 0 |
| Deferred Tax Liabilities | 0 | 0 | 0 | 0 | 0 |
| Deferred Revenue (Non-current) | 8.74M | 6.58M | 0 | 0 | 0 |
| Other Non-current Liabilities | 8.02M | 61.95M | 94.22M | 108.9M | 104.42M |
| Total Non-current Liabilities | 68.03M | 258.7M | 284.17M | 299.72M | 277.46M |
| Total Liabilities | 405.62M | 583.06M | 678.45M | 703.49M | 683.1M |
| Common Stock | 319K | 324K | 303K | 282K | 262K |
| Retained Earnings | (216.51M) | (34.23M) | (173.35M) | (98.65M) | (76.83M) |
| Accumulated OCI | (758K) | (14.52M) | (3.75M) | (1.35M) | 3.48M |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 |
| Total Equity | 2.21B | 2.49B | 2.26B | 2.24B | 2.16B |
| Total Debt | 51.27M | 190.17M | 189.94M | 190.82M | 173.04M |
| Net Debt | (595.9M) | (311.03M) | (73.05M) | (26.55M) | (309.45M) |
Exelixis, Inc.
NASDAQ:EXEL
Intrinsic Alpha fair value
Locked
Current Price
$68.29
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.